NCT02357810 - Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas | Biotech Hunter

Enrollment

178

Participants

Timeline

Start Date

March 21, 2015

Primary Completion Date

April 27, 2018

Study Completion Date

October 12, 2021

Conditions

Adult LiposarcomaMetastatic LiposarcomaMetastatic OsteosarcomaRecurrent Adult Soft Tissue SarcomaRecurrent LiposarcomaRecurrent OsteosarcomaStage IV Adult Soft Tissue Sarcoma

Interventions

DRUG

Pazopanib Hydrochloride

Given PO

DRUG

Oral Topotecan Hydrochloride

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (8)

52242

University of Iowa Hospitals and Clinics, Iowa City

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

55905

Mayo Clinic, Rochester

60045

Northwestern University- Lake Forest Hospital, Lake Forest

60611

Northwestern University, Chicago

63110

Washington University School of Medicine, St Louis

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville